SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy.

Front Immunol · 2024 · PMC11688394 · PMID 39744626

Europe PMC DOI

hedged sentence

0.8020

closest p · 16.0× alpha

0.8020

boldest claim

The sentences

showed a trendp=0.802not close (p > 0.1)

T cell responses in the intake group, however, showed a trend towards higher S activated CD8 + T cell frequencies (T FH p=0.802, T H p=0.802, CD8 + p=0.235).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.